Related Experiment Video
Updated: Nov 27, 2025
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.5K
[Bladder cancer immunological background and biomarkers.]
Mar Valés-Gómez1, Gloria Esteso1, María José Felgueres1
1Departamento de Inmunología y Oncología. Centro Nacional de Biotecnología (CNB-CSIC). Madrid. España.
Archivos Espanoles De Urologia
|December 3, 2020
Summary
Bladder cancer immunotherapy, like Bacillus Calmette-Guérin (BCG), harnesses the immune system. Understanding its mechanisms can improve treatments and predict patient responses to new immunotherapies.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Bladder cancer treatment has historically benefited from immune stimulation.
- Bladder tumors exhibit high antigenicity, suggesting susceptibility to immunotherapy.
- Studying immune responses to bladder cancer treatment informs current and future therapies.
Purpose of the Study:
- To examine the immune response to Bacillus Calmette-Guérin (BCG) treatment in non-muscle invasive bladder cancer.
- To correlate BCG treatment mechanisms with emerging immunotherapies.
- To understand patient variability in response and tolerance to immunotherapy.
Main Methods:
- Review of immune system activities relevant to cancer.
- Analysis of BCG treatment for bladder cancer, including mechanism of action and biomarkers.
- Summary of historical observations leading to monoclonal antibody immunotherapy.
- Description of current immunotherapies for bladder cancer.
Main Results:
- BCG treatment stimulates an immune response in bladder cancer.
- High antigenic load in bladder tumors predicts immunotherapy response.
- Variability in patient response and tolerance to immunotherapy is observed.
Conclusions:
- Understanding BCG's mechanism provides insights into bladder cancer immunotherapy.
- New immunotherapies, including monoclonal antibodies, are advancing bladder cancer treatment.
- Further research is needed to optimize immunotherapy efficacy and patient selection.
